Table 3.
The levels of sVILIP-1, sNSE, and sCAV-1 among four patient subgroups and control group.
| Groups | Cases | sVILIP-1 (pg/ml) | sNSE (ng/ml) | sCAV-1 (pg/ml) |
|---|---|---|---|---|
| Control group | 29 | 38.77 (32.59, 44.90) | 3.52 (2.77, 5.04) | 54.26 (28.76, 71.89) |
| A group | 10 | 61.67 (53.15, 82.18)# | 4.67 (3.64, 5.98) | 108.84 (90.96, 186.12)# |
| B group | 22 | 77.90 (56.17, 92.34)# | 5.47 (3.94, 6.90)* | 132.14 (110.32, 187.43)# |
| C group | 17 | 70.97 (51.98, 107.35)# | 5.16 (3.89, 8.57)* | 130.84 (84.98, 232.47)# |
| D group | 9 | 79.55 (56.67, 100.84)# | 4.48 (3.75, 7.66) | 130.84 (95.59, 231.82)# |
Patient group was divided into 4 subgroups according to the interval between sample collection and end of seizure: A (3–12 h), B (12–24 h), C (24–48 h), D (48–72 h); Data represented as median (interquartile range);
#
P < 0.01,
*
P < 0.05, compared with control group.